Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264600 | 1.00 | HTR1A (0.36) | HTR1ANT5ECTSLCTSBCTSK | |
| SCHEMBL259089 | 0.84 | HTR1A (0.35) | HTR1ANT5ECTSLCTSBCTSK | |
| SCHEMBL264608 | 0.84 | HTR1A (0.35) | HTR1ANT5ECTSLCTSBCTSK | |
| SCHEMBL12253790 | 0.83 | HTR1A (0.37) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL14453213 | 0.82 | HTR1A (0.38) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL13650055 | 0.82 | HTR1A (0.38) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL13695333 | 0.80 | PDE4D (0.40) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL3174043 | 0.80 | PDE4D (0.40) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL259838 | 0.80 | PDE4D (0.40) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL16756812 | 0.80 | PDE4D (0.40) | HTR1ANT5ETACR2GJB2SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | HTR1A 4285/4885NT5E 170/4885CTSL 4034/4885 |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | HTR1A 2378/4885NT5E 179/4885CTSL 2428/4885 |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | DPYD, TYMP, TYMS | HTR1A 4285/4885NT5E 170/4885CTSL 4034/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | HTR1A 4285/4885NT5E 170/4885CTSL 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.